N
Nancy Y. Ip
Researcher at Hong Kong University of Science and Technology
Publications - 390
Citations - 37404
Nancy Y. Ip is an academic researcher from Hong Kong University of Science and Technology. The author has contributed to research in topics: Cyclin-dependent kinase 5 & Neurotrophin. The author has an hindex of 78, co-authored 381 publications receiving 34323 citations. Previous affiliations of Nancy Y. Ip include University of Cambridge & Chinese Academy of Sciences.
Papers
More filters
Patent
Assay system for degenerative muscle disease
TL;DR: In this paper, an assay system useful for detecting denervated or degenerating muscle by measuring the amount of soluble ciliary neurotrophic factor receptor in body fluids is described, which can be used to detect denervation or degeneration.
Patent
Probes for the detection of rflp in eucaryotic genomes
Nancy Y. Ip,Howard J. Baum +1 more
TL;DR: In this paper, a method for obtaining polynucleotide sequences which are useful for detecting Variable Tandem Repeat polymorphism at multiple genetic loci and other genetic analyses under high stringency conditions (hence, with high specificity) is described.
Patent
Human monoclonal antibodies against epha4 and their use
TL;DR: In this article, the binding properties of human EphA4 monoclonal antibodies with distinct binding characteristics are described, including antigen binding fragments, bispecific forms of these antibodies, and conjugates.
Journal ArticleDOI
A tacrine-tetrahydroquinoline heterodimer potently inhibits acetylcholinesterase activity and enhances neurotransmission in mice
Fanny C.F. Ip,Guangmiao Fu,Fengzhi Yang,Fangyuan Kang,Peiran Sun,Choi Ying Ling,Kit Cheung,Fangzhou Xie,Yueqing Hu,Lei Fu,Nancy Y. Ip +10 more
TL;DR: In this paper, the authors used 6-chlorotacrine and the tetrahydroquinolone moiety of huperzine A to design and synthesize a series of heterodimers that inhibit AChE at nanomolar potency.
Patent
Receptor modulators exhibiting neuroprotective and memory enhancing activities
TL;DR: In this paper, the authors provide therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in treating central nervous system disorders by over-activation of NMDA or MC receptors.